Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.56B 16.19B 15.15B 28.41B 1,889B 29B 195B 75.27B 934B 75.2B 73.56B 3,237B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.94B 17.45B 16.34B 30.64B 2,037B 31.28B 210B 81.18B 1,007B 81.09B 79.32B 3,491B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+3.32%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
133.99
10 years 10.54
Extreme 10.54
159.54
Date Insider Type Main position Quantity % Market Cap.
03-22Issuer sale

Director

28,899 0.0151%
03-22Issuer sale

Director

20,558 0.0108%
03-22Issuer sale

Director

17,169 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+102.06%+13.27% 20.03B
+1.17%+11.56%+121.34%+131.62% 4.67B
+2.02%+18.71%+69.57%+206.39% 3.24B
-4.54%-2.42%-30.43%-41.97% 2.05B
-0.83%+1.97%+137.93%-45.02% 1.88B
+2.01%+13.57%+47.49%+238.69% 1.44B
-3.68%+12.38%+147.90%-53.94% 903M
-3.95%-2.78%-20.34%+31.46% 872M
-1.09%-7.70%-37.42%-22.22% 472M
-8.07%-34.43%+6.75% - 471M
Average -1.60%+2.69%+54.48%+50.92% 3.6B
Weighted average by Cap. +0.34%+3.10%+88.90%+47.54%

Financials

2024 2025
Net sales 2.76B 2.42B 2.23B 2.09B 3.91B 260B 4B 26.8B 10.37B 129B 10.36B 10.13B 446B 3.25B 2.85B 2.62B 2.46B 4.61B 306B 4.7B 31.54B 12.2B 151B 12.19B 11.93B 525B
Net income -1.03B -902M -832M -778M -1.46B -97.05B -1.49B -9.99B -3.87B -47.97B -3.86B -3.78B -166B -208M -182M -168M -157M -295M -19.62B -301M -2.02B -782M -9.69B -781M -764M -33.62B
Net Debt 1.74B 1.52B 1.4B 1.31B 2.47B 164B 2.52B 16.88B 6.53B 81.01B 6.53B 6.38B 281B 1.57B 1.38B 1.27B 1.19B 2.23B 148B 2.27B 15.25B 5.9B 73.2B 5.9B 5.77B 254B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock